Published in N Engl J Med on October 22, 1992
Adverse effects of salmeterol in asthma: a neuronal perspective. Thorax (2009) 2.12
Antithetic regulation by beta-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway beta-agonist paradox. J Clin Invest (2003) 1.87
Adenosine bronchoprovocation: a promising marker of allergic inflammation in asthma? Thorax (1997) 1.65
Protective effects of a glucocorticoid on downregulation of pulmonary beta 2-adrenergic receptors in vivo. J Clin Invest (1995) 1.41
Functional antagonism: tolerance produced by inhaled beta 2 agonists. Thorax (1996) 1.26
Pharmacokinetics and extrapulmonary beta 2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers. Thorax (1997) 1.13
Desensitization of beta2-adrenoceptor-mediated responses by short-acting beta2-adrenoceptor agonists in human lung mast cells. Br J Pharmacol (2003) 1.13
Albuterol-induced downregulation of Gsalpha accounts for pulmonary beta(2)-adrenoceptor desensitization in vivo. J Clin Invest (2000) 1.04
Adenosine monophosphate and histamine induced bronchoconstriction: repeatability and protection by terbutaline. Thorax (1997) 1.02
Trends in asthma mortality among African Americans and whites in Chicago, 1968 through 1991. Am J Public Health (1994) 0.99
Systemic and bronchodilator effects of inhaled rac-formoterol in subjects with chronic obstructive pulmonary disease: a dose-response study. Br J Clin Pharmacol (2008) 0.98
Changes in methacholine induced bronchoconstriction with the long acting beta 2 agonist salmeterol in mild to moderate asthmatic patients. Thorax (1993) 0.97
Influence of agonist intrinsic activity on the desensitisation of beta2-adrenoceptor-mediated responses in mast cells. Br J Pharmacol (2004) 0.92
Antagonism of long-acting beta2-adrenoceptor agonism. Br J Clin Pharmacol (2002) 0.92
Add-on therapy with montelukast or formoterol in patients with the glycine-16 beta2-receptor genotype. Br J Clin Pharmacol (2003) 0.92
The long-acting beta-adrenoceptor agonist, indacaterol, inhibits IgE-dependent responses of human lung mast cells. Br J Pharmacol (2009) 0.91
Retracted S-nitrosoglutathione supplementation to ovalbumin-sensitized and -challenged mice ameliorates methacholine-induced bronchoconstriction. Am J Physiol Lung Cell Mol Physiol (2011) 0.91
Desensitisation of mast cell beta2-adrenoceptor-mediated responses by salmeterol and formoterol. Br J Pharmacol (2003) 0.90
Salmeterol tachyphylaxis in steroid treated asthmatic subjects. Thorax (1996) 0.89
Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma. Br J Clin Pharmacol (2003) 0.88
Management of asthma in adults: current therapy and future directions. Postgrad Med J (2003) 0.88
Assessment of different methods of inhalation from salbutamol metered dose inhalers by urinary drug excretion and methacholine challenge. Br J Clin Pharmacol (2005) 0.86
Bronchodilators and bronchial hyperresponsiveness. Thorax (1994) 0.86
Functional effects of long-term activation on human beta 2- and beta 3-adrenoceptor signalling. Br J Pharmacol (1995) 0.84
Epidemiologic study of an outbreak of clenbuterol poisoning in Catalonia, Spain. Public Health Rep (1995) 0.84
Chronic asthma. BMJ (2001) 0.81
Combination of budesonide/formoterol on demand improves asthma control by reducing exercise-induced bronchoconstriction. Thorax (2013) 0.80
Beta agonists and ventilation. Thorax (1993) 0.79
Effects of terbutaline on basal thermogenesis of human skeletal muscle and Na-K pump after 1 week of oral use--a placebo controlled comparison with propranolol. Br J Clin Pharmacol (1993) 0.78
Tolerance with beta 2-adrenoceptor agonists: time for reappraisal. Br J Clin Pharmacol (1995) 0.78
Sympathomimetic agents and airway hyperreactivity. N Engl J Med (1993) 0.75
Asthma therapy--future promise and current practice. West J Med (1995) 0.75
Long-acting beta 2-agonists. Role in primary care asthma treatment. Can Fam Physician (1997) 0.75
Effects of cessation of terbutaline treatment on airway obstruction and responsiveness in patients with chronic obstructive pulmonary disease. Thorax (1996) 0.75
Continuous Inhalation of Ipratropium Bromide for Acute Asthma Refractory to β2-agonist Treatment. J Pediatr Pharmacol Ther (2015) 0.75
Effect of an inhaled glucocorticosteroid on mast cell and smooth muscle beta 2 adrenergic tolerance in mild asthma. Thorax (1998) 0.75
Sympathomimetics and airway hyperreactivity. Thorax (1994) 0.75
The effect of glycopyrronium and indacaterol, as monotherapy and in combination, on the methacholine dose-response curve of mild asthmatics: a randomized three-way crossover study. Respir Res (2017) 0.75
Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J (2008) 10.08
Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med (1997) 8.48
Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med (1996) 5.53
Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med (2001) 5.47
Increased nitric oxide in exhaled air of asthmatic patients. Lancet (1994) 5.39
Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J (2008) 5.38
Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet (2001) 5.25
Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J (2005) 5.24
Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond) (1998) 4.31
Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. Lancet (2001) 3.48
Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med (1999) 3.44
Asthma as an axon reflex. Lancet (1986) 3.26
Single-dose slow-release aminophylline at night prevents nocturnal asthma. Lancet (1982) 3.21
Exhaled markers of pulmonary disease. Am J Respir Crit Care Med (2001) 3.14
Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol (2000) 3.13
Neural control of human airways in health and disease. Am Rev Respir Dis (1986) 2.97
Exhaled and nasal nitric oxide measurements: recommendations. The European Respiratory Society Task Force. Eur Respir J (1997) 2.79
Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med (1997) 2.77
Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax (1998) 2.71
Exacerbations of chronic obstructive pulmonary disease. Eur Respir J (2007) 2.65
Bradykinin-induced bronchoconstriction in humans. Mode of action. Am Rev Respir Dis (1987) 2.64
Cytokines in asthma. Thorax (1999) 2.64
Effects of inhaled platelet activating factor on pulmonary function and bronchial responsiveness in man. Lancet (1986) 2.41
Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med (2000) 2.33
Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Am J Respir Crit Care Med (1996) 2.32
Acute and chronic effects of cigarette smoking on exhaled nitric oxide. Am J Respir Crit Care Med (1995) 2.28
Circulating catecholamines in exercise and hyperventilation induced asthma. Thorax (1981) 2.22
Exhaled carbon monoxide in childhood asthma. J Pediatr (1999) 2.19
Activation and localization of transcription factor, nuclear factor-kappaB, in asthma. Am J Respir Crit Care Med (1998) 2.19
Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. FASEB J (2001) 2.18
Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J (2004) 2.18
STAT4 activation in smokers and patients with chronic obstructive pulmonary disease. Eur Respir J (2004) 2.06
Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD. Eur Respir J (2002) 2.04
Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med (2000) 2.03
The effect of airway epithelium on smooth muscle contractility in bovine trachea. Br J Pharmacol (1985) 1.98
Oxidative stress reduces histone deacetylase 2 activity and enhances IL-8 gene expression: role of tyrosine nitration. Biochem Biophys Res Commun (2004) 1.98
Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med (1999) 1.96
Expression of inducible nitric oxide in human lung epithelial cells. Biochem Biophys Res Commun (1994) 1.96
Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1999) 1.94
Increased 8-isoprostane, a marker of oxidative stress, in exhaled condensate of asthma patients. Am J Respir Crit Care Med (1999) 1.92
Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am J Respir Crit Care Med (1997) 1.91
A calcium antagonist, nifedipine, modifies exercise-induced asthma. Thorax (1981) 1.90
Autoradiographic visualization of beta-adrenoceptor subtypes in human lung. Am Rev Respir Dis (1985) 1.89
T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients. Clin Exp Immunol (2009) 1.89
Tumor necrosis factor-alpha increases airway responsiveness and sputum neutrophilia in normal human subjects. Am J Respir Crit Care Med (1995) 1.84
A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med (1997) 1.84
Induction of cyclo-oxygenase-2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone. Br J Pharmacol (1994) 1.82
Increased nitric oxide in exhaled air of normal human subjects with upper respiratory tract infections. Eur Respir J (1995) 1.80
Brittle asthma. Thorax (1998) 1.77
Importance of inhaler devices in the management of airway disease. Respir Med (2007) 1.76
Evidence for systemic rather than pulmonary effects of interleukin-5 administration in asthma. Thorax (2001) 1.76
Airway inflammation after controlled exposure to diesel exhaust particulates. Am J Respir Crit Care Med (2000) 1.75
Circulating catecholamines in acute asthma. Br Med J (Clin Res Ed) (1985) 1.73
Is immunotherapy for asthma worthwhile? N Engl J Med (1996) 1.72
Effect of inhaled corticosteroids on bones and growth. Eur Respir J (1998) 1.68
Supplementary oxygen in healthy subjects and those with COPD increases oxidative stress and airway inflammation. Thorax (2004) 1.68
Reproducibility of exhaled nitric oxide measurements in healthy and asthmatic adults and children. Eur Respir J (2003) 1.68
Elevated levels of exhaled nitric oxide in bronchiectasis. Am J Respir Crit Care Med (1995) 1.67
Pseudo-steroid resistant asthma. Thorax (1999) 1.67
Nitric oxide is the endogenous neurotransmitter of bronchodilator nerves in humans. Eur J Pharmacol (1992) 1.67
Allergen-induced late asthmatic reactions are associated with elevation of exhaled nitric oxide. Am J Respir Crit Care Med (1995) 1.67
Late response to allergen is associated with increased concentrations of tumor necrosis factor-alpha and IL-5 in induced sputum. J Allergy Clin Immunol (1997) 1.65
Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-1alpha, granulocyte-macrophage colony-stimulating factor, and interferon-gamma release from alveolar macrophages in asthma. Am J Respir Crit Care Med (1998) 1.65
Prostaglandin D2 potentiates airway responsiveness to histamine and methacholine. Am Rev Respir Dis (1986) 1.65
Increased exhaled nitric oxide in asthma is mainly derived from the lower respiratory tract. Am J Respir Crit Care Med (1996) 1.65
Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD. Thorax (2009) 1.65
Exhaled nitric oxide: a new lung function test. Thorax (1996) 1.64
Evidence for involvement of NF-kappaB in the transcriptional control of COX-2 gene expression by IL-1beta. Biochem Biophys Res Commun (1997) 1.63
Adenosine as a vasodilator in primary pulmonary hypertension. Circulation (1991) 1.63
Low-dose theophylline reduces eosinophilic inflammation but not exhaled nitric oxide in mild asthma. Am J Respir Crit Care Med (2001) 1.63
Raised levels of exhaled carbon monoxide are associated with an increased expression of heme oxygenase-1 in airway macrophages in asthma: a new marker of oxidative stress. Thorax (1998) 1.63
Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared with non-severe asthma. Thorax (2008) 1.62
Bronchoconstrictor response to inhaled capsaicin in humans. J Appl Physiol (1985) (1985) 1.61
Exhaled nitric oxide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1998) 1.60
Effect of low-dose theophylline plus beclometasone on lung function in smokers with asthma: a pilot study. Eur Respir J (2009) 1.59
Haplotype associated with low interleukin-10 production in patients with severe asthma. Lancet (1998) 1.59
Exhaled carbon monoxide and nitric oxide in COPD. Chest (2001) 1.58
Dose-response curves to inhaled beta-adrenoceptor agonists in normal and asthmatic subjects. Br J Clin Pharmacol (1983) 1.58
Capsazepine inhibits cough induced by capsaicin and citric acid but not by hypertonic saline in guinea pigs. J Appl Physiol (1985) (1995) 1.58
Specific immunological and bronchopulmonary responses following intradermal sensitization to free trimellitic anhydride in guinea pigs. Clin Exp Allergy (1992) 1.57
Effect of inhaled furosemide on metabisulfite- and methacholine-induced bronchoconstriction and nasal potential difference in asthmatic subjects. Am Rev Respir Dis (1990) 1.57
Bradykinin-induced airway microvascular leakage and bronchoconstriction are mediated via a bradykinin B2 receptor. Am Rev Respir Dis (1990) 1.57
Exhaled leukotrienes and prostaglandins in COPD. Thorax (2003) 1.55
Loop diuretics and asthma. Pulm Pharmacol (1992) 1.55
The need to improve inhalation technique in Europe: a report from the Aerosol Drug Management Improvement Team. Respir Med (2006) 1.54
Defective macrophage phagocytosis of bacteria in COPD. Eur Respir J (2009) 1.52
Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet (2001) 1.52
Increased levels of the chemokines GROalpha and MCP-1 in sputum samples from patients with COPD. Thorax (2002) 1.51
Effect of platelet-activating factor on airway vascular permeability: possible mechanisms. J Appl Physiol (1985) (1987) 1.50
Effects of cyclo-oxygenase inhibition on exhaled eicosanoids in patients with COPD. Thorax (2005) 1.50
Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma. J Exp Med (1995) 1.47
Effect of a nitric oxide synthase inhibitor and a glucocorticosteroid on exhaled nitric oxide. Am J Respir Crit Care Med (1995) 1.47
Resveratrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through an NF-kappaB-independent mechanism. FASEB J (2005) 1.47
Increased pulmonary alpha-adrenergic and reduced beta-adrenergic receptors in experimental asthma. Nature (1980) 1.46
Xanthine oxidase inhibition reduces reactive nitrogen species production in COPD airways. Eur Respir J (2003) 1.46
Measurement of plasma histamine in asthma. Clin Allergy (1983) 1.46
Bradykinin-evoked sensitization of airway sensory nerves: a mechanism for ACE-inhibitor cough. Nat Med (1996) 1.45
Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers. Regulation by interleukin-10. Am J Respir Crit Care Med (2000) 1.44